Autopsy report · NCT03111758

Flow Augmentation Study in Postthrombotic Patients

“Reaching total sample size was not feasible within the anticipated time frame.”

The sponsor’s own words in the registry.

Life of this trial

• Ran for about 4 years 4 months before it stopped.
• 10 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Na

Sponsor

Maastricht University Medical Center

Sponsor type

University, hospital or other

Conditions

Postthrombotic Syndrome

Interventions

Flow augmentation

Participants

10

Sites

1

Countries

Netherlands

Trials that died the same way

• Physical Exercise for Augmenting Cognitive Health (PEACH)
  “The study protocol was not feasible. We made several modifications but halted the study prematurely before we met our target sample size goal.” (70% match in meaning)
• Phase II Trial for Patients With Loco-Regional Esophageal Carcinoma
  “The study was unable the accrue the required number of patients within a reasonable time.” (65% match in meaning)
• Short-course Antibiotic Treatment in Gram-positive Cocci Infective Endocarditis
  “Inability to reach the estimated sample size” (64% match in meaning)
• Visionaire: A Prospective Study
  “An interim analysis found the study would not be able to reach significance without a large increase in subjects which was not feasible.” (64% match in meaning)
• A Prospective Investigation of Pleth Variability Index (PVI) as a Dynamic Parameter of Fluid Responsiveness in Children
  “Recruitment was too slow and data collected would not add to already published studies.” (63% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.